Latest news and press releases about Bluejay Diagnostics, Inc. (BJDX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force.
Price
| Price | $0.81 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.18 |
| EV / EBITDA | 1.21 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -125.01% |
| Return on Invested Capital | -77.55% |
| Return on Assets | -63.04% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BCTXZ · ELAB · MLEC · MSPR · NKGN · TIVC · UPC
Explore sector: Healthcare · Medical - Devices
More sections of BJDX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks